1.Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RTN, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med. 2017; 43:750–763.
2.Citerio G, Bakker J, Bassetti M, Benoit D, Cecconi M, Curtis JR, et al. Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition. Intensive Care Med. 2014; 40:147–159.
3.Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015; 41:1411–1423.
4.Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care. 2007; 11:218.
5.Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006; 10:222.
6.Rice TW, Wheeler AP. Coagulopathy in critically ill patients: part 1: platelet disorders. Chest. 2009; 136:1622–1630.
7.Wheeler AP, Rice TW. Coagulopathy in critically ill patients: part 2-soluble clotting factors and hemostatic testing. Chest. 2010; 137:185–194.
8.Levi M, Sivapalaratnam S. Hemostatic abnormalities in critically ill patients. Intern Emerg Med. 2015; 10:287–296.
9.Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B. E. S. T. kidney) investigators. Intensive Care Med. 2007; 33:1563–1570.
10.Kidney Disease. Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl. 2012; 2:1–138
11.Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005; 20:1416–21.
12.Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009; 361:1627–1638.
13.Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med. 2015; 43:1622–1629.
14.Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol. 2003, 16:566–571.
15.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8:336–341.
16.Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.
17.GA. W, B. S, D. OC. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Clinical epidemiology program. The Ottawa Hospital Research Institute. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 20 Apr 2019.
18.Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html. Accessed 25 May 2019.
19.Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135.
20.Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018; 27:1785–1805.
21.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560.
22.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088–1101.
23.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–634.
24.Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med. 1993; 19:329–332.
25.Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis. 1994; 24:806–812.
26.Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000; 26:1652–1657.
27.Holt AW, Bierer P, Glover P, Plummer JL, Bersten AD. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med. 2002; 28:1649–1655.
28.Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous Venovenous Hemofiltration Without Anticoagulation. ASAIO J. 2004; 50:76–80.
29.Palsson R, Laliberte KA, Niles JL. Choice of replacement solution and anticoagulant in continuous venovenous hemofiltration. Clin Nephrol. 2006; 65:34–42.
30.Nurmohamed SA, Vervloet MG, Girbes ARJ, Ter Wee PM, Groeneveld ABJ. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: A prospective study. Blood Purif. 2007; 25:316–323.
31.Agarwal B, Shaw S, Shankar Hari M, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol. 2009; 51:504–509.
32.Kleger GR, Fässler E. Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs. 2010; 33:139–146.
33.Nagarik AP, Soni SS, Adikey GK, Raman A. Comparative study of anticoagulation versus saline flushes in continuous renal replacement therapy. Saudi J Kidney Dis Transpl. 2010; 21:478–483.
34.Panphanpho S, Naowapanich S, Ratanarat R. Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant. J Med Assoc Thai. 2011; 94 Suppl 1:S105–110.
35.Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012; 34:279–285.
36.Chua HR, Baldwin I, Bailey M, Subramaniam A, Bellomo R. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure. J Crit Care. 2012; 27:744.e747–715.
37.Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, Strampelli E, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care. 2012, 16:R111.
38.Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs. 2013; 36:208–216.
39.Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 2014; 9:e108737.
40.Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk a randomized clinical trial. Medicine (Baltimore). 2015; 94:e2392.
41.Schilder L, Nurmohamed SA, Ter Wee PM, Paauw NJ, Girbes ARJ, Beishuizen A, et al. Coagulation, Fibrinolysis and Inhibitors in Failing Filters during Continuous Venovenous Hemofiltration in Critically Ill Patients with Acute Kidney Injury: Effect of Anticoagulation Modalities. Blood Purif. 2015; 39:297–305.
42.Sanz Ganuza M, Hidalgo F, García-Fernández N. Circuit life span of continuous renal replacement therapy in critically ill patients with or without conventional anticoagulation: An observational prospective study. An Sist Sanit Navar. 2017; 40:77–84.
43.Nash DM, Przech S, Wald R, O’Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care. 2017; 41:138–144.
44.Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med. 2013; 39:2135–2143.
45.Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017; 18:69.
46.Treichl B, Bachler M, Lorenz I, Friesenecker B, Oswald E, Schlimp CJ, et al. Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis. Semin Thromb Hemost. 2015; 41:61–67.
47.Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2016; 42:505–520.
48.Zhang W, Bai M, Yu Y, Li L, Sun S, Chen X, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019; 23:22.
49.Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999; 55:1991–1997.
50.Balik M, Waldauf P, Plasil P, Pachl J. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif. 2005; 23:325–329.
51.Cubattoli L, Teruzzi M, Cormio M, Lampati L, Pesenti A. Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs. 2007; 30:244–252.
52.Kalb R, Kram R, Morgera S, Slowinski T, Kindgen-Milles D. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial. 2013; 17:202–212.
53.Nurmohamed SA, Jallah BP, Vervloet MG, Yldirim G, ter Wee PM, Groeneveld AB. Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study. BMC Nephrol. 2013; 14:89.
54.Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, et al. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007; 49:642–649.
55.Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016; 20:144.
56.Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997; 109:123–127.
57.Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003; 31:2450–2455.
58.Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer HH, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care. 2014; 29:265–271.
59.Khadzhynov D, Dahlinger A, Schelter C, Peters H, Kindgen-Milles D, Budde K, et al. Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. Crit Care Med. 2017; 45:e941-e946.
60.Tan JN, Haroon SWP, Mukhopadhyay A, Lau T, Murali TM, Phua J, et al. Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. J Intensive Care Med. 2019; 34:418–425.
61.Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003; 7:483–485.
62.Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron. 1993; 64:376–381.
63.Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail. 2009; 31:668–675.
64.Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015; 38:595–599.
65.Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs. 2016; 39:16–21.
66.Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study. Kobe J Med Sci. 2017; 63:E30-e36.
67.Dunn WJ, Sriram S. Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables. Crit Care Resusc. 2014; 16:225–231.
68.Fealy N, Aitken L, du Toit E, Lo S, Baldwin I. Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. Crit Care med. 2017; 45:e1018-e1025.
69.Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359:7–20.
70.Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009; 361:1627–1638.
71.Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017; 18:69.